Skip to main content
Premium Trial:

Request an Annual Quote

Recuro Health Acquires 'Health Intelligence' Firm MyLifeIQ

NEW YORK – Recuro Health said Wednesday that it has acquired MyLifeIQ, a startup maker of a pre-launch epigenetics-based "health intelligence platform" for consumers. Terms were not disclosed.

Dallas-based Recuro Health said that it has already integrated MyLifeIQ's technology into its own digital health software. Recuro CEO and founder Michael Gorton had hinted at the acquisition in an interview with GenomeWeb in June.

MyLifeIQ, also based in Dallas, has been beta testing its platform, asking testers to take a DNA test, wear a digital health sensor, and answer occasional surveys.

"The benefits of participating include DNA results and a simple analysis about how to put it to action in your life in the areas like exercise, foods, sleep, mood, stress, digestion, and overall health," according to the MyLifeIQ beta site.

"By fine-tuning environmental elements like exercise, food, sleep, and medications, we match these factors with the DNA to create a high-performing body," Gina Fioretti, executive director of Recuro's genomics division, said in a statement. "Our objective is to make life easier by providing an actionable, personalized guidebook that improves health and vitality."

Recuro, itself less than 2 years old, entered the genomics market in June with the acquisition of Family Care Path, a Cleveland Clinic spinout that makes MyLegacy, a web-based clinical decision support and risk stratification application for genomics.

In early May, Recuro announced that it had acquired UDoTest, software developed to match physicians, payors, employers, and patients with labs that offer self-collection testing services for more than 80 diseases. Recuro this year also bought SupDoc, a startup that supports virtual behavioral health and virtual primary care.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.